Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.

Abstract

This study aimed to document the first-in-human application of a ⁶⁸Ga-labeled heterodimeric peptide BBN-RGD (bombesin-RGD) that targets both integrin α_vβ₃ and gastrin-releasing peptide receptor (GRPR). We evaluated the safety and assessed the clinical diagnostic value of ⁶⁸Ga-BBN-RGD PET/CT in prostate cancer patients in comparison with ⁶⁸Ga-BBN. Five healthy volunteers (4 men and 1 woman; age range, 28-53 y) were enrolled to validate the safety of ⁶⁸Ga-BBN-RGD. Dosimetry was calculated using the OLINDA/EXM software. Thirteen patients with prostate cancer (4 newly diagnosed and 9 posttherapy) were enrolled. All the patients underwent PET/CT scans 15-30 min after intravenous injection of 1.85 MBq (0.05 mCi) per kilogram of body weight of ⁶⁸Ga-BBN-RGD and also accepted ⁶⁸Ga-BBN PET/CT within 2 wk for comparison. With a mean injected dose of 107.3 ± 14.8 MBq per patient, no side effect was found during the whole procedure and 2 wk follow-up, demonstrating the safety of ⁶⁸Ga-BBN-RGD. A patient would be exposed to a radiation dose of 2.90 mSv with an injected dose of 129.5 MBq (3.5 mCi), which is much lower than the dose limit set by the Food and Drug Administration. In 13 patients with prostate cancer diagnosed by biopsy, ⁶⁸Ga-BBN-RGD PET/CT detected 3 of 4 primary tumors, 14 metastatic lymph nodes, and 20 bone lesions with an SUV_max of 4.46 ± 0.50, 6.26 ± 2.95, and 4.84 ± 1.57, respectively. Only 2 of 4 primary tumors, 5 lymph nodes, and 12 bone lesions were positive on ⁶⁸Ga-BBN PET/CT, with the SUV_max of 2.98 ± 1.24, 4.17 ± 1.89, and 3.61 ± 1.85, respectively. This study indicates the safety and efficiency of a new type of dual integrin α_vβ₃- and GRPR-targeting PET radiotracer in prostate cancer diagnosis and staging.